GleamWall
中文EN

BNGO Bionano Genomics, Inc.

Laboratory Analytical Instruments · Nasdaq · SEC CIK 1411690 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.2%
TTM net income YoY22.0%
TTM EPS YoY84.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin48.0%
Operating margin-97.1%
Net margin-96.9%
FCF margin—
EBITDA margin-76.0%

Returns

ROE-77.2%
ROA-48.0%
ROIC (approx.)-67.6%
Asset turnover0.50x

Leverage & solvency

Liabilities / assets39.1%
Debt / equity0.00x
Current ratio2.07x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-17.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$8.28M$8.17M$6.69M$7.95M$7.37M$6.73M$6.46M$8.16M
Cost of revenue$4.33M$3.86M$3.44M$4.55M$4.00M$3.26M$3.52M$4.75M
Gross profit$3.95M$4.31M$3.25M$3.40M$3.37M$3.48M$2.94M$3.42M
R&D expense$3.04M$2.99M$3.14M$3.23M$2.84M$2.93M$2.37M$3.47M
SG&A expense$7.44M$8.54M$8.01M$8.71M$9.06M$8.35M$9.03M$11.75M
Operating income-$6.54M-$7.22M-$7.90M-$8.54M-$8.54M-$7.80M-$8.46M-$11.94M
Pretax income-$6.45M-$7.42M-$8.29M-$7.90M-$8.49M-$6.85M-$3.10M-$20.12M
Income tax$8,000$7,000$10,000$35,000$14,000$10,000$7,000$1,000
Net income-$6.45M-$7.42M-$8.30M-$7.93M-$8.50M-$6.86M-$3.10M-$20.12M
EBITDA-$5.64M-$6.22M-$5.59M-$6.20M-$7.54M-$6.80M-$6.03M-$9.54M
EPS (basic)-0.54-0.64-0.76—-1.59-1.99-1.15—
EPS (diluted)-0.54-0.64-0.76—-1.59-1.99-1.15—
Weighted avg. shares (diluted)11.99M11.55M10.98M—5.34M3.44M2.69M—
Balance sheet
Cash & equivalents$4.36M$3.73M$3.42M$2.99M$3.06M$3.56M$3.62M$9.17M
Short-term investments$3.81M$6.19M$10.98M$16.28M$18.52M$12.88M$14.61M$302,000
Receivables$5.85M$4.37M$4.13M$5.20M$4.53M$3.49M$3.35M$4.75M
Inventory$8.70M$7.01M$7.69M$7.83M$8.42M$10.31M$11.42M$13.28M
Current assets$25.52M$24.88M$38.98M$45.39M$48.80M$42.66M$44.93M$39.49M
PP&E, net$12.23M$13.02M$14.04M$14.85M$16.17M$17.26M$18.34M$19.22M
Intangibles$325,000$1.67M$3.00M$4.34M$5.68M$7.03M$8.37M$9.71M
Total assets$46.29M$47.59M$64.80M$73.58M$79.06M$76.01M$78.41M$76.67M
Current liabilities$12.31M$10.04M$21.23M$22.94M$22.98M$24.18M$26.41M$37.34M
Total liabilities$18.08M$15.98M$27.34M$29.16M$29.26M$30.64M$30.23M$41.30M
Shareholders' equity$28.21M$31.61M$37.46M$44.42M$49.80M$45.37M$48.19M$35.38M
Shares outstanding13.51M11.78M11.28M10.74M9.73M3.91M3.10M1.87M
Cash flow statement
Operating cash flow-$4.52M-$4.67M-$5.72M-$4.17M-$5.92M-$3.49M-$2.76M-$6.50M
Investing cash flow$2.41M$13.68M$5.46M$4.01M-$4.67M$1.98M-$14.07M$3.00M
Financing cash flow$2.74M-$9.69M$657,000$1.60M$10.08M$1.47M$10.89M$3.89M
Depreciation & amortization$900,000$1.00M$2.31M$2.34M$1.00M$1.00M$2.43M$2.40M
Stock-based compensation$299,000$970,000$670,000$926,000$941,000$1.08M$1.59M$1.94M

Free plan shows the latest 8 periods; Pro shows all 40 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.